American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 1

Azziz, 2009, The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report, Fertil Steril, 91, 456, 10.1016/j.fertnstert.2008.06.035

Rosner, 1997, Errors in the measurement of plasma free testosterone, J Clin Endocrinol Metab, 82, 2014, 10.1210/jcem.82.6.9999

Rosner, 2001, An extraordinarily inaccurate assay for free testosterone is still with us, J Clin Endocrinol Metab, 86, 2903, 10.1210/jcem.86.6.7643

Vermeulen, 1999, A critical evaluation of simple methods for the estimation of free testosterone in serum, J Clin Endocrinol Metab, 84, 3666, 10.1210/jcem.84.10.6079

Carmina, 2006, Ovarian and adrenal hyperandrogenism, Ann N Y Acad Sci, 1092, 130, 10.1196/annals.1365.011

Carmina, 2007, Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes, J Endocrinol Invest, 30, 111, 10.1007/BF03347408

Stanczyk, 1991, Is 11 beta-hydroxyandrostenedione a better marker of adrenal androgen excess than dehydroepiandrosterone sulfate?, Am J Obstet Gynecol, 165, 1837, 10.1016/0002-9378(91)90042-P

Vesper, 2009, Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods, Steroids, 74, 498, 10.1016/j.steroids.2009.01.004

Janse, 2011, Assessment of androgen concentration in women: liquid chromatography-tandem mass spectrometry and extraction RIA show comparable results, Eur J Endocrinol, 165, 925, 10.1530/EJE-11-0482

Rosner, 2007, Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement, J Clin Endocrinol Metab, 92, 405, 10.1210/jc.2006-1864

Carmina, 2010, The diagnosis of polycystic ovary syndrome in adolescents, Am J Obstet Gynecol, 203, 201.e1, 10.1016/j.ajog.2010.03.008

Azziz, 1998, Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama, Fertil Steril, 70, 274, 10.1016/S0015-0282(98)00141-1

Carmina, 1999, Do hyperandrogenic women with normal menses have polycystic ovary syndrome?, Fertil Steril, 71, 319, 10.1016/S0015-0282(98)00455-5

Hull, 1982, The value of a single serum progesterone measurement in the midluteal phase as a criterion of a potentially fertile cycle (“ovulation”) derived from treated and untreated conception cycles, Fertil Steril, 37, 355, 10.1016/S0015-0282(16)46095-4

Abraham, 1974, Evaluation of ovulation and corpus luteum function using measurements of plasma progesterone, Obstet Gynecol, 44, 522

Dumesic, 2013, Cancer risk and PCOS, Steroids, 78, 782, 10.1016/j.steroids.2013.04.004

Fauser, 2012, Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group, Fertil Steril, 97, 28, 10.1016/j.fertnstert.2011.09.024

Veltman-Verhulst, 2012, Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies, Hum Reprod Update, 18, 638, 10.1093/humupd/dms029

Dewailly, 2014, Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society, Hum Reprod Update, 20, 334, 10.1093/humupd/dmt061

Balen, 2003, Ultrasound assessment of the polycystic ovary: international consensus definitions, Hum Reprod Update, 9, 505, 10.1093/humupd/dmg044

Duijkers, 2010, Polycystic ovaries, as defined by the 2003 Rotterdam consensus criteria, are found to be very common in young healthy women, Gynecol Endocrinol, 26, 152, 10.3109/09513590903247824

Johnstone, 2010, The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance, J Clin Endocrinol Metab, 95, 4965, 10.1210/jc.2010-0202

Chen, 2008, Ovarian volume and follicle number in the diagnosis of polycystic ovary syndrome in Chinese women, Ultrasound Obstet Gynecol, 32, 700, 10.1002/uog.5393

Carmina, 2010, Hirsutism: investigation and management, Expert Rev Endocrinol Metab, 5, 189, 10.1586/eem.09.73

Dewailly, 2011, Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries, Hum Reprod, 26, 3123, 10.1093/humrep/der297

Hatch, 1981, Hirsutism: implications, etiology, and management, Am J Obstet Gynecol, 140, 815, 10.1016/0002-9378(81)90746-8

Rosenfield, 1995, Role of androgens in the developmental biology of the pilosebaceous unit, Am J Med, 98, 80S, 10.1016/S0002-9343(99)80063-1

Borgia, 2004, Correlation between endocrinological parameters and acne severity in adult women, Acta Derm Venereol, 84, 201, 10.1080/00015550410023248

Timpatanapong, 1997, Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne, J Dermatol, 24, 223, 10.1111/j.1346-8138.1997.tb02778.x

Lucky, 1983, Plasma androgens in women with acne vulgaris, J Invest Dermatol, 81, 70, 10.1111/1523-1747.ep12539043

Goodman, 2001, American Association of Clinical Endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders, Endocr Pract, 7, 120, 10.4158/EP.7.2.120

Brown, 2009, Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne, Cochrane Database Syst Rev, 2, CD000194

Yemisci, 2005, Effects and side-effects of spironolactone therapy in women with acne, J Eur Acad Dermatol Venereol, 19, 163, 10.1111/j.1468-3083.2005.01072.x

Yeon, 2011, 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss, J Eur Acad Dermatol Venereol, 25, 211, 10.1111/j.1468-3083.2010.03758.x

Lakryc, 2003, The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism, Gynecol Endocrinol, 17, 57, 10.1080/gye.17.1.57.63

Paparodis, 2011, The Hirsute woman: challenges in evaluation and management, Endocr Pract, 17, 807, 10.4158/EP11117.RA

Iorizzo, 2006, Finasteride treatment of female pattern hair loss, Arch Dermatol, 142, 298, 10.1001/archderm.142.3.298

Olszewska, 2005, Effective treatment of female androgenic alopecia with dutasteride, J Drugs Dermatol, 4, 637

Legro, 2013, Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 98, 4565, 10.1210/jc.2013-2350

Williams, 2013, Polycystic ovarian syndrome during puberty and adolescence, Mol Cell Endocrinol, 373, 61, 10.1016/j.mce.2013.01.005

Hardy, 2013, Diagnosis of adolescent polycystic ovary syndrome, Steroids, 78, 751, 10.1016/j.steroids.2013.04.011

Hickey, 2011, Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis, Hum Reprod, 26, 1469, 10.1093/humrep/der102

Hsia, 2012, Unlicensed use of metformin in children and adolescents in the UK, Br J Clin Pharmacol, 73, 135, 10.1111/j.1365-2125.2011.04063.x

Geller, 2011, State of the art review: emerging therapies: the use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS), Int J Pediatr Endocrinol, 2011, 9, 10.1186/1687-9856-2011-9

Bridger, 2006, Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome, Arch Pediatr Adolesc Med, 160, 241, 10.1001/archpedi.160.3.241

Roe, 2013, Using the androgen excess-PCOS society criteria to diagnose polycystic ovary syndrome and the risk of metabolic syndrome in adolescents, J Pediatr, 162, 937, 10.1016/j.jpeds.2012.11.019

Bredella, 2013, Impact of metformin monotherapy versus metformin with oestrogen-progesterone on lipids in adolescent girls with polycystic ovarian syndrome, Clin Endocrinol (Oxf), 79, 199, 10.1111/cen.12028

Ibáñez, 2000, Premature adrenarche--normal variant or forerunner of adult disease?, Endocr Rev, 21, 671

Ibáñez, 2004, Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome, J Pediatr, 144, 23, 10.1016/j.jpeds.2003.08.015

Ibáñez, 2011, Early metformin therapy (age 8–12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence, J Clin Endocrinol Metab, 96, E1262, 10.1210/jc.2011-0555

Ibáñez, 2005, Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women, Hum Reprod, 20, 1833, 10.1093/humrep/dei004

Bechtold, 2012, Effect of antiandrogen treatment on bone density and bone geometry in adolescents with polycystic ovary syndrome, J Pediatr Adolesc Gynecol, 25, 175, 10.1016/j.jpag.2011.11.010

Harmanci, 2013, Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome, Clin Endocrinol (Oxf), 78, 120, 10.1111/j.1365-2265.2012.04466.x